Grund Nicholas

SEC source: 0001661887-26-000002 · primarydocument.xml · nonDerivative · entry 2

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 561,750

F1 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2025.

F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.

SEC source: 0001661887-26-000002 · primarydocument.xml · nonDerivative · entry 1

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 592,994

F1 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2025.

F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.

SEC source: 0001661887-26-000001 · primarydocument.xml · derivative · entry 2

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,000

Underlying: Common Stock · 320,000 shares

Expires 2036-01-30

F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

SEC source: 0001661887-26-000001 · primarydocument.xml · nonDerivative · entry 1

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 646,579

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

SEC source: 0001562180-25-000914 · primarydocument.xml · nonDerivative · entry 2

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 442,579

F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.

F3 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2024.

SEC source: 0001562180-25-000914 · primarydocument.xml · derivative · entry 3

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 292,300

Underlying: Common Stock · 292,300 shares

Expires 2035-01-31

F4 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

SEC source: 0001562180-25-000914 · primarydocument.xml · nonDerivative · entry 1

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 498,200

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

SEC source: 0001562180-24-000983 · primarydocument.xml · derivative · entry 2

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 454,950

Underlying: Common Stock · 454,950 shares

Expires 2034-01-31

F2 · derivative.exercise_date: The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

SEC source: 0001562180-24-000983 · primarydocument.xml · nonDerivative · entry 1

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 303,300

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

SEC source: 0000792977-19-000044 · wf-form4_155182696960170.xml · nonDerivative · entry 1

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,805

F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,333 restricted stock units on March 2, 2019.

SEC source: 0000792977-19-000027 · wf-form4_155130977417748.xml · derivative · entry 3

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2029-02-25

F3 · price: Not applicable.

F5 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter.

SEC source: 0000792977-19-000027 · wf-form4_155130977417748.xml · nonDerivative · entry 2

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,787

F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer").

F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending February 25, 2022 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award.

F3 · price: Not applicable.

SEC source: 0000792977-19-000027 · wf-form4_155130977417748.xml · nonDerivative · entry 1

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,787

F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer").

F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the "Plan") that will vest in three equal annual installments with the first installment vesting on February 25, 2020.

F3 · price: Not applicable.

SEC source: 0000792977-19-000023 · wf-form4_155122119573585.xml · nonDerivative · entry 1

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,787

F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,333 restricted stock units on February 23, 2019.

SEC source: 0000792977-19-000005 · wf-form4_154698202175358.xml · nonDerivative · entry 1

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,769

F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 10,669 restricted stock units on January 4, 2019.

SEC source: 0001179110-18-003693 · edgar.xml · derivative · entry 4

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2028-03-02

F3 · price: Not applicable.

F6 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter.

SEC source: 0001179110-18-003693 · edgar.xml · nonDerivative · entry 3

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,324

F5 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 10,666 RSUs on January 4, 2018 and 3,333 RSUs on February 23, 2018. Due to the black-out policies implemented by the Issuer, the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until March 2, 2018, at which time an aggregate of 4,193 shares were withheld to satisfy the reporting person's applicable tax obligations.

SEC source: 0001179110-18-003693 · edgar.xml · nonDerivative · entry 2

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,517

F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer").

F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending March 1, 2021 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award.

F3 · price: Not applicable.

SEC source: 0001179110-18-003693 · edgar.xml · nonDerivative · entry 1

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,517

F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer").

F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on March 2, 2019.

F3 · price: Not applicable.

SEC source: 0001179110-17-006983 · edgar.xml · nonDerivative · entry 1

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,517

F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 10,665 restricted stock units ("RSUs") on January 4, 2017. Due to the black-out policies implemented by AMAG Pharmaceuticals, Inc. (the "Issuer"), the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until May 8, 2017, at which time 3,483 shares were withheld to satisfy the reporting person's applicable tax obligations.

SEC source: 0001179110-17-003321 · edgar.xml · derivative · entry 3

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2027-02-23

F3 · price: Not applicable.

F5 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter.

SEC source: 0001179110-17-003321 · edgar.xml · nonDerivative · entry 2

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,000

F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer").

F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending December 31, 2019, subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award.

F3 · price: Not applicable.

SEC source: 0001179110-17-003321 · edgar.xml · nonDerivative · entry 1

Grund Nicholas · CIK 0001661887 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000

F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer").

F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on February 23, 2018.

F3 · price: Not applicable.